Get the Stockscreener App
1.24
0.81%
0.01
After Hours:
1.20
-0.04
-3.23%
Vivani Medical Inc stock is traded at $1.24, with a volume of 127.88K.
It is up +0.81% in the last 24 hours and down -12.68% over the past month.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
127.88K
Relative Volume:
0.28
Market Cap:
$111.85M
Revenue:
-
Net Income/Loss:
$-27.09M
P/E Ratio:
-3.0723
EPS:
-0.4036
Net Cash Flow:
$-26.52M
1W Performance:
+4.20%
1M Performance:
-12.68%
6M Performance:
+9.73%
1Y Performance:
-13.29%
1-Day Range:
$1.23
$1.26
1-Week Range:
$1.20
$1.31
52-Week Range:
$0.9228
$1.92
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
415-506-8462
Address
1350 S. LOOP ROAD, ALAMEDA
Compare VANI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.24 | 111.85M | 0 | -27.09M | -26.52M | -0.4036 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivani Medical Inc Stock (VANI) Latest News
Form 424B5 Vivani Medical Inc For: 25 September - Investing.com India
Form 424B5 Vivani Medical Inc For: 25 September By Investing.com - Investing.com UK
Vivani Medical Expects Cortigent Sale to ClearOne to Close in October 2026 - Minichart
Vivani Medical announces anticipated October closing of Cortigent merger with ClearOne - Investing.com Nigeria
Vivani Medical Announces Merger Deal Involving Cortigent - TipRanks
Form 8K Vivani Medical Inc For: 16 September By Investing.com - Investing.com Canada
Vivani Medical at H.C. Wainwright conference: implant pitch gains pace - investing.com
This Vivani Medical Insider Increased Their Holding By 17% Last Year - simplywall.st
Vivani Medical (NASDAQ:VANI) Trading Down 9.1%Here's What Happened - MarketBeat
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative
Two New York conferences are planned for Vivani Medical - Stock Titan
Vivani Medical Announces Participation in Upcoming Investor Conferences - GlobeNewswire
VANI Stock Price, Quote & Chart - ChartMill
Vivani (VANI) Quarter in Review: EPS Lands Above Forecast in the Latest Session; Trading Response - Vinanet
Form 8K Vivani Medical Inc For: 17 August By Investing.com - Investing.com Nigeria
Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached - TradingView
Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market - Bitget
Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold" - MarketBeat
Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal - foreignpolicyjournal.com
VANI Q1 2026 Earnings: Narrower Loss Slightly Beats Consensus, Shares Rise 4.48%Balance Sheet Strength - vinanet.vn
Vivani Medical allows Novo Nordisk to evaluate NPM-139 - scanx.trade
Vivani Medical Fully Enrolls Phase 1 Semaglutide Implant Trial; Data Due November - Minichart
Vivani Medical gets approval to initiate SLIM-1 trial - scanx.trade
Form 8K Vivani Medical Inc For: 13 August By Investing.com - Investing.com Nigeria
Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Vivani Medical Q2 losses narrow 41% YoY; signs Novo Nordisk deal - scanx.trade
Vivani Medical: Q2 Earnings Snapshot - Barchart.com
Vivani Medical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027 - Stock Titan
ClearOne (CLRO) details Cortigent reverse merger, 78% Vivani control and new equity plan - Stock Titan
ClearOne to merge with Cortigent, pivoting to neurotech under new Nasdaq ticker - Dealroom
Vivani Medical Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ClearOne Inc. (CLRO) majority holder cancels warrant as Cortigent merger proceeds - Stock Titan
Form 8K Vivani Medical Inc For: 6 August By Investing.com - Investing.com Nigeria
Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial - marketscreener.com
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial - TipRanks
Form 8K Vivani Medical Inc For: 6 August - Investing.com India
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - The Manila Times
Semaglutide implant trial doses all 20 participants; data expected in November - Stock Titan
ClearOne Cancels 437,500 First Finance Warrants at $5.00 Amid Cortigent Merger Process - TradingView
Vivani Medical (VANI) to Announce Earnings on Wednesday - MarketBeat
Vivani Medical (VANI) Dips 1.54% to $1.28, Holding Within Key $1.22 Support and $1.34 Resistance Range - careplusvn.com
Enterprise value to EBITDA forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Vivani Medical, Inc. Revenue Breakdown – NASDAQ:VANI - TradingView
Vivani Medical Inc (VANI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 4 Vivani Medical Inc For: 30 July By Investing.com - Investing.com Nigeria
Vivani Medical (VANI) awards CEO 200K stock options and 100K RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) grants COO options and performance RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) awards CFO 75,000 options and RSUs - Stock Titan
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):